• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier

    6/20/25 7:30:00 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email
    • Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and fruit, and reported significantly improved health status.
    • Abbott's Healthy Food Rx community-focused "food is medicine" program provides home-delivered healthy food boxes and nutrition education in Stockton, Calif., where 60% of the population has diabetes or pre-diabetes.

    CHICAGO, June 20, 2025 /PRNewswire/ -- Late-breaking research presented at the American Diabetes Association's 85th Scientific Sessions showed that Abbott's (NYSE:ABT) Healthy Food Rx "food is medicine" program helped people living with diabetes to eat better and feel healthier, with participants reporting improved diet quality and health status.

    This study is one of the few randomized controlled clinical trials examining the impact of food is medicine programs. Conducted by the Public Health Institute Center for Wellness and Nutrition (PHI CWN), this clinical trial assessed the impact of Abbott's Healthy Food Rx in a highly food insecure, low-income, community-based setting of 364 people living with diabetes over a six-month period. The Healthy Food Rx program provides home-delivered, meal-based healthy food boxes accompanied by nutrition education to help address diabetes.

    Key study results include:

    • Improved diet quality: Healthy Food Rx participants reported significantly increased vegetable consumption compared to the control group (0.37 vs. 0.03 increased servings per day; p = 0.007), and increased fruit consumption compared to control group (0.3 vs. 0.2 increased servings per day, p = 0.232).
    • Improved health status: Healthy Food Rx participants reported significantly greater improvements in self-reported physical health status over six months (from 38% to 63%, p < 0.001), compared to the control group (from 47% to 50%, p=0.453; between group p<0.001).
    • Lowered A1C levels in both groups: A1C levels significantly improved for both Healthy Food Rx participants and the control group. A1C is a test that reflects average glucose levels for the past three months; levels decreased by 0.7% and 1.2%, in the intervention group and control group, respectively. Both values exceeded the widely accepted 0.5% benchmark that is considered a clinically significant change and is associated with improved health outcomes in people with diabetes.
    • Participants were strongly satisfied with Healthy Food Rx, and shared with family and friends. Participants in Abbott's Healthy Food Rx reported strong satisfaction – 98% were satisfied with the program and 97% used all or most of the food. Two-thirds of participants (67%) shared the food with two or more people, and 99% were likely to recommend the program to others.

    "Living with diabetes in an economically underserved community can present numerous challenges, from limited access to affordable, healthy foods to a lack of appropriate health services," said Erika Takada, Executive Director, Public Health Institute Center for Wellness and Nutrition. "Even with a program that reaches participants just twice a month, we are seeing benefits in people with diabetes eating better foods and feeling healthier. This underscores the foundational role that good nutrition can play in helping to address the impact of diabetes and other chronic diseases on our families and communities."

    Launched in 2021, Abbott's Healthy Food Rx is one of the largest community-focused food is medicine programs in the country, reaching more than 1,700 participants to date. These clinical trial findings build on results of an earlier 12-month study that showed clinically important benefits among Healthy Food Rx participants living with diabetes.

    "Programs like Abbott's Healthy Food Rx are critically important in communities like Stockton where diabetes incidence and risk are significantly higher," said Kwabena O. Adubofour, MD, FACP, Internal Medicine Specialist and a Board Certified Diabetologist at Community Medical Centers (CMC) in Stockton. "From results like A1C reduction to even personal well-being, participants from the CMC clinic benefited greatly from access to healthy foods and nutrition resources. It will be important to see how these benefits translate into long-term improvements in diabetes outcomes so people can lead healthier, fuller lives."

    "We're pleased that results from Abbott's Healthy Food Rx can contribute to a better understanding of the impacts that programs like this can have for people living with diabetes," said Melissa Brotz, president of Abbott Fund and senior vice president of Global Marketing and External Affairs at Abbott. "By integrating healthy food and nutrition education as part of a broader effort to remove barriers to care, we're helping people to feel more in control and take an active role in managing their health."

    About the Clinical Trial

    A delayed intervention randomized clinical trial design was used. Participants were recruited by health educators and randomized into two groups: the intervention group received home-delivered, meal-based food boxes once every other week for six months with nutrition education in the form of recipes, cooking videos and text messages; the control group received the intervention after the six-month study period. All participants received usual care, including potential medication prescriptions and optional diabetes education and social needs referrals.

    Participants were administered surveys at enrollment and after six months, with hemoglobin A1C assessed as the primary outcome, and secondary outcomes including fruit and vegetable intake, food security and health status. Study results can be found here.

    About Abbott's Healthy Food Rx

    Abbott's Healthy Food Rx program is part of the company's Future Well™ Communities initiative, a multi-year effort to advance health access by removing the barriers that prevent people with diabetes from living healthy lives.

    Abbott partnered with PHI CWN to design and implement Healthy Food Rx with Stockton-based organizations, with funding support from Abbott's foundation, Abbott Fund. CMC, a local federally qualified health center in Stockton, identified potential Healthy Food Rx participants. Program participants received food boxes from the Emergency Food Bank Stockton/San Joaquin (EFB), delivered directly to their home every other week for six months. The boxes included ingredients for a family-sized healthy meal with lean protein, vegetables and fruits, as well as pantry staples such as beans, rice and nuts. The box also contained a recipe card and link to an optional online cooking class with EFB, which provided additional guidance and diabetes education.

    About the Public Health Institute and the Center for Wellness and Nutrition

    The Public Health Institute, an independent nonprofit organization, advances wellbeing and health equity with communities around the world. PHI develops research, leadership and partnerships to build strong public health policy, programs, systems and practices. For more information, visit phi.org. The Center for Wellness and Nutrition (CWN, centerforwellnessandnutrition.org), a program of the Public Health Institute, is a national leader in developing campaigns, programs and partnerships to promote wellness and equitable practices in the most vulnerable communities in California and across the country.

    About Abbott and Abbott Fund

    Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

    Abbott Fund is a philanthropic foundation established by Abbott in 1951. Abbott Fund's mission is to create healthier global communities by investing in creative ideas that promote science, expand access to healthcare and strengthen communities worldwide. For more information on Abbott Fund, visit www.abbottfund.org.

    Cision View original content:https://www.prnewswire.com/news-releases/new-research-on-abbotts-healthy-food-rx-program-shows-food-is-medicine-approach-helps-people-living-with-diabetes-eat-better-and-feel-healthier-302487489.html

    SOURCE Abbott

    Get the next $ABT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    6/16/2025$143.00Market Perform
    Leerink Partners
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    5/30/2023$112.00Overweight → Equal-Weight
    Morgan Stanley
    4/20/2023$125.00 → $127.00Overweight
    Barclays
    More analyst ratings

    $ABT
    SEC Filings

    See more
    • SEC Form 11-K filed by Abbott Laboratories

      11-K - ABBOTT LABORATORIES (0000001800) (Filer)

      6/20/25 4:05:52 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Abbott Laboratories

      SD - ABBOTT LABORATORIES (0000001800) (Filer)

      5/29/25 11:01:45 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Laboratories filed SEC Form 8-K: Leadership Update

      8-K - ABBOTT LABORATORIES (0000001800) (Filer)

      5/1/25 4:01:21 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier

      Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and fruit, and reported significantly improved health status.Abbott's Healthy Food Rx community-focused "food is medicine" program provides home-delivered healthy food boxes and nutrition education in Stockton, Calif., where 60% of the population has diabetes or pre-diabetes.CHICAGO, June 20, 2025 /PRNewswire/ -- Late-breaking research presented at the American Diabetes Association's 85th Scientific Sessions showed that Abbott's (NYSE:ABT) Healthy Food Rx "food is medicine" program helped people living with diabetes

      6/20/25 7:30:00 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Receives Health Canada Authorization for Whole Blood Rapid Test to Help Assess Suspected Concussions

      The test, run on Abbott's portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), otherwise known as concussionThe test produces lab-quality results in 15 minutesClinicians can get a result at the patient's bedside, making the test accessible at urgent care clinics and healthcare settings outside of the hospital emergency roomThe test can be used to help evaluate patients up to 24 hours after injuryMISSISSAUGA, ON, June 16, 2025 /CNW/ -- Abbott (NYSE:ABT) announced today that Health Canada has approved the company's i-STAT TBI test cartridge for use with whole blood, helping clinicians to assess suspected concussio

      6/16/25 8:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Declares 406th Consecutive Quarterly Dividend

      ABBOTT PARK, Ill., June 13, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 406th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio

      6/13/25 11:34:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Abbott Labs with a new price target

      Leerink Partners initiated coverage of Abbott Labs with a rating of Market Perform and set a new price target of $143.00

      6/16/25 8:17:39 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Abbott Labs with a new price target

      Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00

      10/8/24 7:11:39 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Abbott Labs with a new price target

      Piper Sandler initiated coverage of Abbott Labs with a rating of Overweight and set a new price target of $131.00

      9/19/24 7:31:59 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blount Sally E. sold $337,116 worth of Common shares without par value (2,600 units at $129.66), decreasing direct ownership by 7% to 34,058 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      5/2/25 5:04:05 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Stratton John G was granted 1,635 units of Common shares without par value, increasing direct ownership by 9% to 19,033 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      4/29/25 6:30:29 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Starks Daniel J was granted 1,635 units of Common shares without par value, increasing direct ownership by 0.02% to 6,728,817 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      4/29/25 6:22:08 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

      For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

      10/24/23 3:52:17 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care